SCHEDULE: Deep Track Capital Discloses 5.5% Stake in Akero Therapeutics

Deep Track Capital, LP and its affiliates have reported a passive 5.5% ownership stake in Akero Therapeutics, Inc., holding 4.4 million shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 4,400,000 shares of Akero Therapeutics, Inc. common stock.
• This represents 5.50% of Akero Therapeutics' outstanding common stock.
• The ownership is passive, with no intent to change or influence control of the issuer, as certified by the reporting persons.
• The shares are held with shared voting power of 4,400,000 and shared dispositive power of 4,400,000.
• The percentage of class is calculated based on 79,988,975 common shares outstanding as of July 31, 2025, as reported in Akero Therapeutics' 10-Q filing.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a specialized investment firm like Deep Track Capital is generally viewed positively, as it signals institutional confidence in the company's value proposition without indicating an intent to disrupt management.

Positives

• A specialized biotechnology investment firm, Deep Track Capital, has taken a significant passive stake, indicating institutional confidence in Akero Therapeutics' long-term prospects.
• The investment by a prominent institutional investor could attract further institutional interest and potentially enhance market visibility for Akero Therapeutics.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Akero Therapeutics or the reporting persons regarding the company's future performance or strategic direction, beyond the passive nature of the investment.

Industry Context

The investment by Deep Track Capital, a firm specializing in biotechnology, highlights continued institutional interest and capital allocation towards companies within the biotech sector, particularly those with promising pipelines or market positions like Akero Therapeutics.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract more institutional buying, positively impacting share price.
• Management: The passive nature of the investment indicates no immediate threat to current management or strategic direction, allowing the company to focus on its existing strategy.

Key Dates

Recommendation

The filing indicates a significant passive investment by a specialized biotechnology fund, Deep Track Capital, which suggests institutional confidence in Akero Therapeutics. However, as a Schedule 13G, it does not provide new financial results, operational updates, or strategic guidance from the company itself. Therefore, while the institutional interest is a positive signal, a 'hold' recommendation is appropriate until further fundamental information from Akero Therapeutics becomes available to assess its performance and outlook.

Keywords

Akero Therapeutics, Deep Track Capital, Biotechnology, Institutional Investment, Shareholder Stake, AKRO, SEC Filing, Schedule 13G